The initiation of Phase 1 dosing represents a material de-risking step for OPKO's oncology pipeline. Traders should monitor upcoming safety and early efficacy data readouts, which could serve as catalysts for re-rating, especially in a high-unmet-need setting like relapsed/refractory B-cell lymphoma.
OPK drugs
OPK drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 22 $1.23entry
- T+1 · 7mo ago −0.81%α −0.42% · $1.22
- T+5 · 7mo ago −15.35%α −15.40% · $1.04
- T+20 · 6mo ago −6.50%α −9.67% · $1.15
- T+60 · 4mo ago −3.25%α −8.03% · $1.19
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
OPKO Health announced the initiation of patient dosing in a Phase 1 trial for MDX2003, a novel tetraspecific T-cell engager targeting relapsed or refractory B-cell lymphoma. Preclinical data supporting the trial were presented at major medical conferences, marking a key milestone in the development of this first-in-class therapy.
Key Facts
- OPKO Health subsidiary ModeX Therapeutics has dosed patients in the Phase 1 trial (NCT07249905) of MDX2003, a first-in-class tetraspecific T-cell engager.
- MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells to enhance tumor killing and prevent immune escape in B-cell lymphoma.
- Preclinical data demonstrating potent anti-tumor activity were presented at ASH 2025 and ESMO TAT 2026.
- The study is evaluating safety, tolerability, pharmacokinetics, and immune activity in adult patients with B-cell lymphoma, with dose-escalation and expansion phases.
Financial Impact
No immediate direct financial impact; early-stage clinical advancement may increase optionality and long-term value potential.
Risk Factors
- Clinical trial may encounter safety or tolerability issues, particularly with T-cell engagers known for cytokine release syndrome.
- Early-phase success does not guarantee later-stage efficacy or regulatory approval.
- Dilution risk if future funding rounds or partnerships are required to advance development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278886 |
Track record
10 reports on OPK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 4, 202612d ago 8-K Neutral 6/10 Entry $1.75 Now $1.62 −7.43% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 6/10 No price data
- Oct 15, 20264w ago 8-K Bullish 7/10 Entry $1.53 to $1.68 Now $1.62 +5.88% ▲ +9.80% +10.97% vs SPY
- Jul 27, 202616w ago 8-K Mixed 5/10 Entry $1.65 to $1.49 Now $1.62 −1.82% ▼ −9.70% −13.08% vs SPY
- Jul 23, 202616w ago Press Release Neutral 1/10 Entry $1.17 to $1.46 Now $1.62 +38.46% ▲ +24.79% +21.48% vs SPY
- Jun 15, 202622w ago Press Release Neutral 3/10 Entry $1.40 to $1.23 Now $1.62 +15.71% ▼ −12.14% −11.39% vs SPY
- May 15, 202626w ago DEFA14A Neutral 4/10 Entry $1.13 to $1.39 Now $1.62 +43.36% ▲ +23.01% +21.43% vs SPY
- Apr 30, 202628w ago Press Release Neutral 4/10 Entry $1.13 to $1.43 Now $1.62 +43.36% ▲ +26.55% +21.58% vs SPY
- Apr 22, 202629w ago Press Release Bullish 7/10 Viewing Entry $1.23 to $1.15 Now $1.62 +31.71% ▼ −6.50% −9.67% vs SPY
- Apr 21, 202629w ago Press Release Neutral 1/10 Entry $1.23 to $1.15 Now $1.62 +31.71% ▼ −6.50% −9.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers